Search Results

You are looking at 181 - 190 of 460 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Amanda N. Fader

extent of adjuvant therapy, and managing locoregional recurrence. In fact, laparoscopy has become the gold standard treatment of many gynecologic conditions, “both benign and malignant,” reported Dr. Fader. Many studies have shown improved outcomes with

Full access

Eric Jonasch

not support the use of adjuvant therapy for RCC in 2015. With the advent of various antiangiogenic agents and mTOR inhibitors, investigators have moved past the cytokine therapy era, he noted. In the upcoming years, Dr. Jonasch predicted, the next wave

Full access

Stephen B. Edge and David G. Sheldon

cancer patients receiving no adjuvant therapy . J Clin Oncol 2001 ; 19 : 1468 – 1475 . 37 Gray RJ Cox CE Reintgen DS . Importance of missed axillary micrometastases in breast cancer patients . Breast J 2001 ; 7 : 303 – 307 . 38

Full access

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

Thus, in these high-risk patients, offering SLNB would seem reasonable to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. The significance of tumor regression is debatable, with more recent

Full access

Juan P. Cata and Daniel D. Kim

studies suggest that women aged ≥66 years present a high risk of developing prolonged use of opioids and benzodiazepines. Interestingly, Sakamoto et al 6 found that surgery combined with adjuvant therapies was an independent risk factor for new opioid and

Full access

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Dennis E. Hallahan, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Allan R. Oseroff, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, and Linda C. Wang

survival in early-stage disease—results from a review of 82 consecutive cases diagnosed between 1992 and 2004 . Ann Surg Oncol 2007 ; 14 : 1943 – 1952 . 39 Garneski KM Nghiem P . Merkel cell carcinoma adjuvant therapy: current data support

Full access

Elizabeth J. Cathcart-Rake and Kathryn J. Ruddy

: Lessons From Medicare Part D,” in this issue of JNCCN (page 1509 ) adds to the current literature on cancer care disparities in that it reveals how state-level variability in Medicare Part D benefits influence adjuvant therapy prescriptions

Full access

Ingrid A. Mayer

by progressive disease within 6 months of starting treatment with endocrine therapy in the metastatic setting, or the development of metastatic recurrence during or shortly after completing adjuvant therapy. Secondary (acquired) resistance is

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

Pritchard KI Paterson AHG Fine S . Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor

Full access

Michael B. Streiff

adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group . J Clin Oncol 1996 ; 14 : 2731 – 2737 . 13. Holm T Singnomklao T Rutqvist LE Cedermark B . Adjuvant